7/12/2024  4:59:45 PM Chg. +45.25 Volume Bid4:59:45 PM Ask4:59:45 PM Market Capitalization Dividend Y. P/E Ratio
1,842.75DKK +2.52% 60,062
Turnover: 42.48 mill.
-Bid Size: - -Ask Size: - 121.94 bill.DKK - 27.69

Business description

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin's lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.

Management board & Supervisory board

Prof. Dr. Jan G. J. van de Winkel
Management board
Anthony Pagano, Anthony Mancini, Birgitte Stephensen, Christopher Cozic, Dr. Martine J. van Vugt, Dr. Tahamtan Ahmadi, Judith Klimovsky, M.D.
Supervisory board
Deirdre P. Connelly, Pernille Erenbjerg, Dr. Anders Gersel Pedersen, Dr. Mijke Zachariasse, Paolo Paoletti, M.D., Rolf Hoffmann, Elizabeth O’Farrell, Martin Schultz, Takahiro Hamatani

Company data

Name: Genmab A/S
Address: Kalvebod Brygge 43,DK-1560 Copenhagen
Phone: +45-7020-2728
Fax: +45-7020-2729
E-mail: info@genmab.com
Internet: www.genmab.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: -
IPO date: 10/18/2000

Investor relations

Name: Andrew Carlsen
IR phone: +45-3377-9558
IR Fax: -
IR e-mail: ir@genmab.com

Company calendar

CW 31 | 8/1/2024 Interim Report 2nd Quarter/6 Months
CW 45 | 11/6/2024 Interim Report 3rd Quarter/9 Months

Main Shareholders

BlackRock, Inc.